Abstract
Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 326-334 |
| Number of pages | 9 |
| Journal | Clinical Cancer Research |
| Volume | 6 |
| Issue number | 2 |
| State | Published - Feb 2000 |
ASJC Scopus subject areas
- Oncology
- Cancer Research